CTCécile Tissot

Cécile Tissot

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cécile Tissot has a total of 397 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tau PET Braak staging across the Alzheimer Disease continuum using Flortaucipir and MK6240

    by Andreia Rocha, Carolina Soares, Marina Scop Medeiros, Emma Ruppert, Arthur C. Macedo, Firoza Z. Lussier, Guilherme Povala, Bruna Bellaver, Pamela C.L. Ferreira, Guilherme Bauer-Negrini, et al.

    Tau positron emission tomography (PET) staging is increasingly used to stratify Alzheimer’s disease (AD), yet cross-tracer interchangeability remains unestablished. In a prospective head-to-head study of 682 individuals across the aging-to-AD continuum, we compared tau PET Braak staging derived from [ 18 F]Flortaucipir and [ 18 F]MK6240. While both tracers showed high internal adherence to hierarchical Braak patterns (89-92%), cross-tracer agreement was limited (43%, weighted κ = 0.54) and fell to 14- 23% at early-to-intermediate stages, a key window for therapeutic intervention. Discordance was strongly directional: in over 90% of discordant cases [ 18 F]MK6240 assigned a higher stage, on average approximately one stage above [ 18 F]Flortaucipir. [ 18 F]MK6240 upstaging was associated with greater Aβ burden, adverse plasma biomarker profiles, and worse cognitive performance. Stage-frequency benchmarking against an external neuropathological cohort (N = 4,422) revealed that PET staging lags neuropathology by ∼2 Braak stages for [ 18 F]MK6240 and ∼3 for [ 18 F]Flortaucipir in the early phases of disease, with progressive convergence at later stages. Tau PET Braak staging is internally coherent within tracers but not interchangeable across them, with [ 18 F]MK6240 systematically assigning higher stages than [ 18 F]Flortaucipir. This biologically meaningful discordance, most pronounced at early stages, has direct implications for patient selection and staging for clinical trials and practice, necessitating tracer- aware harmonization strategies.

  • Open Access

    Detection of tau spatial extent using MK6240 and flortaucipir PET

    by Guilherme Povala, Bruna Bellaver, Livia Amaral, Firoza Z. Lussier, Arthur C. Macedo, Pamela C.L. Ferreira, Douglas T. Leffa, Guilherme Bauer-Negrini, Marina Scop Medeiros, Emma Ruppert, et al.

    INTRODUCTION: Tau PET enables in vivo quantification of neurofibrillary tangle spread, yet whether tau spatial extent (TSE) performs comparably across tracers remains unknown. METHODS: We performed a head-to-head comparison of Flortaucipir and MK6240 tau PET in 682 individuals across the AD continuum, quantifying TSE as the percentage of regional voxels exceeding a tracer-specific abnormality threshold and evaluated it as a metric of tracer comparability. RESULTS: MK6240 showed greater TSE than Flortaucipir (CU Aβ+, medial temporal lobe [MTL]: 42% vs 25%; dementia Aβ+, late neocortical: 55% vs 42%), reaching 50% detection probability at lower Aβ burden (Centiloid: MTL, 26 vs 45; late neocortical, 95 vs 118). TSE showed higher associations than SUVR with memory, Aβ PET, and plasma pTau217, particularly in the neo-late composite. Participants with intermediate tau involvement (TSE 25–50%), most below the SUVR positivity thresholds (MTL positivity 10.2–16.9%), had approximately three-fold higher odds of Aβ PET and pTau217 positivity than TSE 0–25% (ORs 2.90–3.46). 53.4% of intermediate Flortaucipir cases (TSE 25–50%) shifted to a higher MK6240 category, and 82.5% of moderately high Flortaucipir cases (50–75%) were classified as near-saturated (75–100%) by MK6240. Neither raw TSE nor raw SUVR was directly interchangeable across tracers, with systematic and proportional bias for both metrics (MTL Deming slope: TSE 1.29; SUVR 2.69). DISCUSSION: TSE showed stronger unadjusted associations than SUVR in selected region- and outcome-specific comparisons, supporting its potential as a complementary measure. Like SUVR, raw TSE values were not directly interchangeable between flortaucipir and MK6240, and tracer-specific calibration and validation are required before cross-tracer use.

  • Open Access

    Ventricular enlargement is associated with early Alzheimer’s disease pathophysiology

    by Seyyed Ali Hosseini, Etienne Aumont, Nesrine Rahmouni, Marcel S Woo, Arthur C Macedo, Brandon Hall, Lydia Trudel, Tevy Chan, Jaime Fernandez Arias, Yi-Ting Wang, et al.

    Alzheimer’s disease (AD) is characterized by progressive brain changes, including protein aggregation and structural changes. Cerebrospinal fluid (CSF) system abnormalities, such as ventricular dilation, increased choroid plexus volume or positron emission tomography (PET) ligand uptake in the CSF, have also been consistently described. We aimed to examine whether changes in CSF production and clearance might be associated with brain protein aggregation across biological stages of Alzheimer’s disease. We hypothesized an association between brain protein aggregation and changes on the CSF system. We examined 378 individuals from the Translational Biomarkers in Aging and Dementia (TRIAD) cohort with T1-weighted magnetic resonance imaging (MRI), amyloid-PET and tau-PET assessments. We assessed the lateral ventricle and choroid plexus volumes, both corrected for intracranial volume, in the MRI native space. Non-specific ventricular tracer standardized uptake value ratio (SUVR), derived from amyloid- and tau-PET images, was used as an indirect marker of choroid plexus-related clearance activity and served as a metric of CSF dynamics. Linear models tested associations amongst lateral ventricular volume (reflecting CSF space enlargement), choroid plexus volume (reflecting secretory tissue morphology) and ventricular SUVR (reflecting tracer activity within the CSF compartment and serving as an indirect marker of choroid plexus-related clearance function and CSF dynamics) with Aβ and tau aggregations. Analyses were restricted to within-modality associations, relating ventricular radioactivity to cortical pathology for each PET tracer. We found that when considered independently, larger ventricular and choroid plexus volumes were associated with higher neocortical Aβ-PET SUVR, particularly in the precuneus and cingulate cortices. Additionally, lower ventricular radioactivity (derived from amyloid-PET) showed strong negative associations in the dorsal apex of the neocortex. However, when all three ventricular parameters were included in the same model, these effects were mediated by ventricular volume. By contrast, the effect of the ventricular parameters on tau load was mediated by Aβ in the neocortex. Therefore, ventricular enlargement appears to be associated with Aβ load. Distinct from neurodegeneration, changes in ventricular parameters, particularly ventricular volume, are associated with upstream Alzheimer’s disease pathophysiology. While ventricular volume significantly mediated ventricular amyloid clearance, no such effect was observed for tau, suggesting distinct clearance mechanisms for these pathologies in Alzheimer’s disease.

  • Open Access

    Distinct molecular trajectories precede amyloid-β and tau pathology in Alzheimer’s disease

    by Marcel Woo, Seyyed Hosseini, Lukas Raich, Nesrine Rahmouni, Etienne Aumont, Arthur Macedo, Stijn Servaes, Brandon Hall, Aurelie Lebrun, Gleb Bezgin, et al.

    Alzheimer’s disease (AD) progresses over a prolonged preclinical phase marked by early amyloid-β pathology (Aβ), followed by tau spread and neurodegeneration. However, limited understanding of longitudinal, stage-specific molecular processes constrains therapeutic timing and patient stratification. Here, we reconstructed molecular trajectories across the AD continuum by integrating longitudinal cerebrospinal fluid (CSF) proteomics with Aβ and tau biomarkers from two independent cohorts. We identified distinct trajectories emerging prior to Aβ and tau conversion. Preclinical Aβ-dominated transitions were characterized by immune- and lipid-associated programs, whereas tau-dominated transitions at the mild cognitive impairment stage were linked to synaptic, proteostatic, and autophagy-related signatures. These stage-specific trajectories predicted biomarker conversion, including from the preclinical, pre-Aβ stage. Longitudinal voxelwise analyses further revealed spatially distinct cortical Aβ and tau patterns corresponding to inflammatory and proteostatic-synaptic signatures. Together, these findings define temporally ordered molecular pathways underlying AD progression and inform stage-specific therapeutic strategies.

  • Open Access

    Clinical–biological Alzheimer's disease stage concordance: insights from cohorts and autopsy data

    by Lydia Trudel, Joseph Therriault, Arthur C Macedo, Seyyed A Hosseini, Jaime Fernandez-Arias, Tevy Chan, Nesrine Rahmouni, Gleb Bezgin, Cécile Tissot, Marcel S Woo, et al.

    Alzheimer's disease (AD) is defined by its characteristic neuropathological changes, which allow for diagnosis and assessment of severity. Recently, the Alzheimer's Association proposed a framework to stage AD biologically based on tau-PET. Furthermore, the framework hypothesizes a degree of alignment between biological AD severity and clinical symptom severity. We aimed to investigate the concordance between clinical and biological stages of AD and explore factors contributing to discordance using in vivo and post-mortem neuropathological data. Data from 768 amyloid-β-positive individuals were drawn from four observational cross-sectional in vivo cohorts (TRIAD, ADNI, HABS-HD and SCAN) in addition to a post-mortem autopsy dataset from the National Alzheimer's Coordinating Center (NACC; n = 3188). All in vivo participants had tau-PET imaging, clinical diagnosis and neurobehavioural assessments. Participants were assigned a biological AD stage based on their tau-PET scan according to the Alzheimer's Association revised criteria stages. The autopsy dataset included individuals with moderate-to-frequent neuritic plaques (CERAD scores 2–3), along with pre-mortem clinical and neurobehavioural data. Clinical–biological concordance was quantified using squared-weighted Cohen's κ. Ordinal and linear regression models assessed associations between biological stage and clinical severity (Clinical Dementia Rating-Sum of Boxes, Mini-Mental State Examination), adjusting for age, sex and cohort. Post-mortem analyses evaluated the impact of comorbid neuropathologies on clinical–biological discordance using adjusted odds ratios and ordinal regression. Overall concordance between clinical and biological AD staging was moderate (Cohen's κ = 0.52, P < 0.001). Approximately 70% of individuals classified as cognitively unimpaired or with dementia exhibited biological stages consistent with their clinical diagnoses. In contrast, transitional decline and mild cognitive impairment groups were more heterogeneous. Notably, 25% of amyloid-β-positive individuals with mild cognitive impairment demonstrated no detectable tau-PET abnormality. Nonetheless, advanced tau-PET stage was reliably associated with clinical impairment. In the NACC autopsy dataset, nearly all individuals with a more severe clinical stage than their proposed biological stage exhibited comorbid neuropathologies, including frontotemporal lobar degeneration (FTLD)-TDP-43, FTLD-tau, Lewy bodies, limbic-predominant age-related TDP-43 encephalopathy (LATE) and cerebrovascular disease. The number of comorbid pathologies was strongly associated with increased odds of clinical dementia (t = 8.45, P < 0.001). Although there is moderate agreement between clinical and biological stages of AD across the entire disease spectrum, strong agreement is found in clinically unimpaired and dementia stages. Comparison of clinical and biological AD stages provides a framework for understanding the large contributions of non-AD neurodegenerative diseases to dementia in amyloid-β-positive individuals. Our results have important implications for clinical trial recruitment strategies and highlight the urgent need for biomarkers for non-AD pathological processes.


  • Open Access

    Glia inflammation and cell death pathways drive disease progression in preclinical and early AD

    by Marcel S Woo, Joseph Therriault, Seyyed Ali Hosseini, Yi-Ting Wang, Arthur C Macedo, Nesrine Rahmouni, Étienne Aumont, Stijn Servaes, Cécile Tissot, Jaime Fernandez-Arias, et al.

    Accumulation of amyloid-β (Aβ) and neurofibrillary tangles (NFTs) are followed by the activation of glia cells and infiltration of peripheral immune cells that collectively accelerate neurodegeneration in preclinical AD models. Yet, the role of neuroinflammation for neuronal injury and disease progression in preclinical and early symptomatic AD remains elusive. Here, we combined multiplexed immunoassays and SomaScan proteomics of the cerebrospinal fluid (CSF) with MRI and PET brain imaging of people across the AD continuum to identify pathways that are associated with AD progression. Unbiased clustering revealed that glia-mediated inflammation, activation of cell death pathways (CDPs) and synaptic pathologies were among the earliest Aβ-induced changes, and were associated with disease progression in preclinical AD. Mediation analysis revealed that activation of CDPs were decisive drivers of inflammation in early symptomatic AD. The cycle of glia-mediated neuroinflammation and neuronal injury characterizes preclinical AD and has implications for novel treatment approaches.


  • Open Access

    Glial reactivity correlates with synaptic dysfunction across aging and Alzheimer’s disease

    by Francieli Rohden, Pamela C. L. Ferreira, Bruna Bellaver, João Pedro Ferrari-Souza, Cristiano S. Aguzzoli, Carolina Soares, Sarah Abbas, Hussein Zalzale, Guilherme Povala, Firoza Z. Lussier, et al.

    Previous studies suggest glial and neuronal changes may trigger synaptic dysfunction in Alzheimer’s disease (AD), but the link between their markers and synaptic abnormalities in the living brain remains unclear. We investigated the association between glial reactivity and synaptic dysfunction biomarkers in cerebrospinal fluid (CSF) from 478 individuals in cognitively unimpaired (CU) and cognitively impaired (CI) individuals. We measured amyloid-β (Aβ), phosphorylated tau (pTau181), astrocyte reactivity (GFAP), microglial activation (sTREM2), and synaptic markers (GAP43, neurogranin). CSF GFAP levels were associated with presynaptic and postsynaptic dysfunction, independent of cognitive status or Aβ presence. CSF sTREM2 levels were related to presynaptic markers in cognitively unimpaired and impaired Aβ+ individuals, and to postsynaptic markers in cognitively impaired Aβ+ individuals. Notably, CSF pTau mediated the relationships between GFAP or sTREM2 and synaptic dysfunction. Our findings, validated in two independent cohorts (TRIAD and ADNI), reveal a distinct pattern of glial contribution to synaptic degeneration.


  • Open Access

    Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer’s disease

    by Sarah Abbas, Pamela C. L Ferreira, Bruna Bellaver, Guilherme Povala, Francieli Rohden, Cristiano Schaffer Aguzzoli, Hussein Zalzale, João Pedro Ferrari-Souza, Douglas T. Leffa, Firoza Z. Lussier, et al.


  • Top Cited Papers
    Open Access

    Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer’s disease

    by Tohidul Islam, Emily Hill, Eric E. Abrahamson, Stijn Servaes, Denis S. Smirnov, Xuemei Zeng, Anuradha Sehrawat, Yijun Chen, Przemysław R. Kac, Hlin Kvartsberg, et al.

    Patients with Alzheimer’s disease (AD) with little or no quantifiable insoluble brain tau neurofibrillary tangle (NFT) pathology demonstrate stronger clinical benefits of therapies than those with advanced NFTs. The formation of NFTs can be prevented by targeting the intermediate soluble tau assemblies (STAs). However, biochemical understanding and biomarkers of STAs are lacking. We show that Tris-buffered saline-soluble tau aggregates from autopsy-verified AD brain tissues include the core sequence ~tau258–368. In neuropathological assessments, antibodies against the phosphorylation sites serine-262 and serine-356 within the STA core almost exclusively stained granular (that is, prefibrillar) tau aggregates in pre-NFTs while antibodies against phosphorylation at serine-202 and threonine-205 and threonine-231, outside the STA core, stained the entire spectrum of tau aggregates in pre-NFTs and mature NFTs, dystrophic neurites and neuropil threads in the hippocampus. Functionally, a recombinantly produced STA core peptide robustly altered neuronal excitability and synaptic transmission in mouse hippocampal brain slices. Furthermore, we developed a cerebrospinal fluid assay that differentiated STAs in AD from non-AD tauopathies, correlated with the severity of NFT burden and cognitive decline independently of amyloid beta deposition, and with tau positron emission tomography uptake across Braak NFT stages. Together, our findings inform about the status of early-stage tau aggregation, reveal aggregation-relevant phosphorylation epitopes in tau and offer a diagnostic biomarker and targeted therapeutic opportunities for AD.


  • Open Access

    Comparison of Plasma p-tau217 and [ 18 F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia

    by Kely Monica Quispialaya, Joseph Therriault, Antonio Aliaga, Andrea L. Benedet, Nicholas J. Ashton, Thomas Karikari, Arthur Cassa Macedo, Nesrine Rahmouni, Cécile Tissot, Jaime Fernandez Arias, et al.

    To compare the diagnostic performance of an immunoassay for plasma concentrations of phosphorylated tau (p-tau) 217 with visual assessments of fluorine-18 fluorodeoxyglucose [18F]FDG-PET in individuals who meet appropriate use criteria for Alzheimer dementia (AD) biomarker assessments. We performed a retrospective analysis of individuals with early-onset (age 18F]FDG-PET scans, amyloid-PET scans, and plasma p-tau217 quantifications. To determine whether the [18F]FDG-PET images were compatible with AD, images were visually rated by 2 nuclear medicine experts. Using a contingency analysis, we evaluated the accuracy of [18F]FDG-PET scan interpretation and plasma p-tau217 for an AD biomarker profile in CSF and for amyloid-PET positivity. A total of 81 individuals with early onset and/or atypical dementia were included in this study (mean age = 65 years; 48/81 female (59%). Both [18F]FDG-PET and plasma p-tau217 showed high levels of agreement with reference standard AD biomarkers ([18F]FDG-PET area under the curve [AUC]: 71%; plasma p-tau217 AUC: 81%). Although both biomarkers had similar specificity for AD [18F]FDG-PET: 70%, CI: 0.56-0.81; plasma p-tau217: 70%, CI: 0.56-0.81), plasma p-tau217 had higher sensitivity for AD (plasma p-tau217: 97%, CI: 0.85-0.99 vs [18F]FDG-PET: 73%, CI: 0.57-0.85) (p = 0.01). Overall accuracy was also higher for plasma p-tau217 (AUC = 84%, CI: 0.75-0.93 vs 72%, CI: 0.60-0.83 of [18F]FDG-PET) (p = 0.02). The same pattern of results was observed when using amyloid-PET as the reference standard. Our study provides evidence that plasma p-tau217 has strong discriminative accuracy for AD among patients with early-onset and/or atypical dementia assessed in specialized settings. Future work should replicate these findings in secondary care settings.